Compare AFG & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFG | QGEN |
|---|---|---|
| Founded | 1872 | 1986 |
| Country | United States | Netherlands |
| Employees | 8700 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 10.2B |
| IPO Year | N/A | 1998 |
| Metric | AFG | QGEN |
|---|---|---|
| Price | $129.34 | $40.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $142.25 | $51.30 |
| AVG Volume (30 Days) | 377.6K | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | 2.75% | ★ 5.97% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.18 |
| Revenue Next Year | $4.61 | $5.66 |
| P/E Ratio | ★ $12.86 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $114.73 | $38.13 |
| 52 Week High | $150.02 | $57.82 |
| Indicator | AFG | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 40.40 |
| Support Level | $127.36 | N/A |
| Resistance Level | $129.56 | $48.60 |
| Average True Range (ATR) | 2.58 | 0.87 |
| MACD | 0.27 | 0.32 |
| Stochastic Oscillator | 81.66 | 74.68 |
American Financial Group Inc is an insurance holding company. Through its subsidiaries, it is engaged in the property and casualty insurance business, focusing on specialized commercial products for businesses. The group operates through two segments: Property and Casualty Insurance, which generates maximum revenue, and Other. The Property and Casualty Insurance segment is further divided into different sub-segments, such as Property and transportation, Specialty casualty, and Specialty financial. These sub-segments offer insurance coverage for vehicles and commercial property, customized programs for small to mid-sized businesses, workers' compensation insurance, risk management insurance programs for lending and leasing institutions, trade credit insurance, and other insurance products.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).